Moolec Science (NASDAQ:MLEC) versus Target Global Acquisition I (NASDAQ:TGAA) Critical Contrast

Moolec Science (NASDAQ:MLEC) and Target Global Acquisition I (NASDAQ:TGAA) are both small-cap consumer staples companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, risk, valuation, analyst recommendations and institutional ownership.

Valuation and Earnings

This table compares Moolec Science and Target Global Acquisition I”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moolec Science	$5.63 million	5.55	-$7.31 million	($0.20)	-4.06
Target Global Acquisition I	N/A	N/A	N/A	N/A	N/A

Target Global Acquisition I has lower revenue, but higher earnings than Moolec Science.

Profitability

This table compares Moolec Science and Target Global Acquisition I’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Moolec Science	-129.97%	-97.95%	-27.91%
Target Global Acquisition I	N/A	N/A	N/A

Risk & Volatility

Moolec Science has a beta of -0.49, indicating that its share price is 149% less volatile than the S&P 500. Comparatively, Target Global Acquisition I has a beta of 0.01, indicating that its share price is 99% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and price targets for Moolec Science and Target Global Acquisition I, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moolec Science	0	0	1	0	3.00
Target Global Acquisition I	0	0	0	0	0.00

Moolec Science presently has a consensus target price of $6.00, suggesting a potential upside of 638.92%. Given Moolec Science’s stronger consensus rating and higher possible upside, equities analysts clearly believe Moolec Science is more favorable than Target Global Acquisition I.

Insider and Institutional Ownership

0.1% of Moolec Science shares are held by institutional investors. Comparatively, 92.1% of Target Global Acquisition I shares are held by institutional investors. 19.9% of Moolec Science shares are held by company insiders. Comparatively, 41.4% of Target Global Acquisition I shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Target Global Acquisition I beats Moolec Science on 6 of the 10 factors compared between the two stocks.

About Moolec Science

Moolec Science SA, a science-based food ingredient company, focuses on developing real animal proteins in plants using molecular farming. It offers Chymosin SPC, a dairy ingredient; GLA SONOVA, a nutritional oil; POORK+, a plant-based, animal meat free ingredient with porcine proteins in soybeans; and BEEF+, a meat replacement product. It operates in the United States, Europe, and South America. The company was founded in 2020 and is based in Luxembourg.

About Target Global Acquisition I

Target Global Acquisition I Corp. does not have significant operations. It focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. It intends to focus on companies operating in the consumer internet, mobility, and financial technology sectors. The company was incorporated in 2021 and is based in Grand Cayman, the Cayman Islands.